CJC-1295: The GHRH Analog That Changed GH Peptide Protocols

There's a reason growth hormone releasing hormone — the signal that tells your pituitary to release GH — isn't used as a therapeutic itself, despite being the most direct way to stimulate GH secretion.

The reason is that it lasts about two minutes in circulation before enzymes destroy it.

CJC-1295 was built to solve that problem. And in solving it, it became one half of the most widely used GH peptide combination in the research space.

The Problem It Was Designed to Solve

GHRH is produced in the hypothalamus and travels a short distance to the anterior pituitary, where it binds to GHRH receptors and triggers GH release. The system works beautifully in vivo — because the hypothalamus delivers GHRH in precise pulses, directly to the pituitary, through a dedicated portal blood system.

The moment you try to administer GHRH systemically — as an injection — the picture changes entirely. Plasma peptidases, particularly dipeptidyl peptidase IV (DPP-IV), cleave GHRH within minutes. By the time an injected dose of native GHRH reaches the pituitary, much of it has been destroyed.

ConjuChem Biotechnologies, a Canadian company, set out to solve this. They developed CJC-1295 — a modified GHRH analog with specific amino acid substitutions that protect the molecule from DPP-IV cleavage. The result: a GHRH analog with a half-life measured in minutes rather than seconds, producing a genuine pulsatile GH response rather than the brief flicker of native GHRH.

Then ConjuChem added the DAC — and created an entirely different compound with an entirely different pharmacological profile. Understanding this distinction is fundamental to understanding CJC-1295.

Two Compounds With the Same Name

This is the most important thing to understand about CJC-1295, and it's the source of more confusion than anything else in the GH peptide space.

CJC-1295 without DAC — also sold as Modified GRF(1-29) or Mod GRF. This is the modified GHRH analog with DPP-IV-resistant substitutions. Half-life: approximately 30 minutes. It produces a sharp, pulsatile GH response that rises and falls over a few hours. This is pharmacologically closest to how endogenous GHRH functions — a pulse, not a sustained elevation.

CJC-1295 with DAC — this is where it gets interesting. DAC stands for Drug Affinity Complex, a ConjuChem technology involving a reactive group (maleimidopropionic acid) that covalently binds to albumin after injection. Albumin circulates in the bloodstream with a half-life of approximately 19 days. Binding to albumin extends CJC-1295's half-life from 30 minutes to 6–8 days.

The consequence: CJC-1295 with DAC doesn't produce GH pulses. It produces a sustained, tonic elevation of GH and IGF-1 that persists for a week after a single injection. This is pharmacologically and physiologically distinct from what the non-DAC version does.

When a vendor sells "CJC-1295" without specifying, they could mean either version. When a protocol calls for "CJC-1295," it could mean either version. This ambiguity has caused genuine confusion — practitioners have followed protocols designed for one version while using the other, with predictably inconsistent results.

If you're evaluating CJC-1295, confirm which version you're working with before anything else.

How It Works

The GHRH receptor pathway. CJC-1295 binds to GHRH receptors in the anterior pituitary — different receptors than ipamorelin's ghrelin receptors. Both peptides ultimately stimulate GH release, but through entirely separate molecular pathways acting on the same pituitary cells.

This receptor-level independence is the mechanistic basis for the synergy between CJC-1295 and ipamorelin. When both receptor systems are activated simultaneously, the GH response is substantially greater than either compound produces alone. This isn't just a theoretical claim — it's been measured.

Amplification of the natural GH pulse. The non-DAC version, administered pre-sleep alongside ipamorelin, amplifies the natural GH pulse in a way that maintains pulsatile physiology. Both compounds are active during the window when GH is naturally being released, and the combined receptor stimulation produces a significantly larger pulse.

Sustained IGF-1 elevation (with DAC). The DAC version creates a different situation: persistent GHRH receptor activation drives chronic GH release and sustained IGF-1 elevation throughout the week between doses. Whether this sustained pattern produces better outcomes than pulsatile stimulation is a genuine open question — there are credible arguments on both sides.

The Human Clinical Data

CJC-1295 with DAC has been studied in human clinical trials — specifically, a Phase 1/2 study published in the Journal of Clinical Endocrinology & Metabolism by Ionescu and Frohman in 2006.

The study enrolled healthy adults and examined CJC-1295 with DAC at multiple doses. Key findings:

Dose-dependent increases in serum GH, peaking at 2–10x baseline
Sustained IGF-1 elevation lasting 1–2 weeks after a single dose, confirming the extended half-life mechanism
No serious adverse events at doses studied
Half-life confirmed at approximately 6–8 days

This is genuine human pharmacokinetic data — not extrapolated from animal models. For the DAC version specifically, ConjuChem's clinical program provides a level of characterization that the non-DAC version doesn't have to the same degree (though the non-DAC version's shorter half-life and simpler mechanism make its pharmacokinetics more predictable from first principles).

ConjuChem's program didn't proceed to approval. The company faced the funding challenges common to small biotech ventures, and the indications being pursued (GH deficiency replacement) faced competition from established products. But the published trial data remains a valuable anchor for understanding this compound.

The DAC vs. No DAC Debate

Practitioners and researchers are genuinely divided on which version is superior for most applications. Here are the honest arguments for each:

The case for no DAC (pulsatile):
The natural GH secretion pattern is pulsatile for a reason. Receptors respond to pulses more efficiently than to constant stimulation — this is a general principle in endocrinology, not specific to GH. Pulsatile GH exposure may produce different downstream effects than tonic elevation. Some evidence suggests that the pulsatile pattern is important for maintaining receptor sensitivity over time. The non-DAC version more closely mimics how the GH axis naturally functions.

The case for DAC (sustained):
Higher average IGF-1 levels throughout the week. Simpler dosing — once or twice weekly rather than daily. The IGF-1 elevation may produce more consistent anabolic and recovery effects than the variability inherent in daily pulsatile protocols. For practitioners managing patients who struggle with daily injections, the convenience is clinically meaningful.

Neither position is obviously correct. The honest answer is that this question hasn't been settled by adequately powered comparative studies in humans.

Protocol

Which version:
Confirm what you have. If it says "Mod GRF(1-29)" or "Modified GRF," it's the non-DAC version. If it says "CJC-1295 with DAC" or simply "CJC-1295 DAC," it's the long-acting version. If it just says "CJC-1295" without clarification, ask the vendor.

CJC-1295 without DAC:

Dose: 100–200 mcg per injection
Combined with ipamorelin 200–300 mcg, administered simultaneously
Pre-sleep, fasted or 2–3 hours post-meal
Once daily; twice daily for more aggressive protocols

CJC-1295 with DAC:

Dose: 1–2 mg per injection
Frequency: Once or twice weekly
Timing matters less than with the non-DAC version — the sustained action means the acute insulin environment at injection time is less critical
Often combined with daily ipamorelin for the GHRP synergy

Cycle considerations: Common approaches run 3-month cycles with periodic breaks. IGF-1 monitoring every 8–12 weeks is the appropriate practice for anyone using these compounds seriously.

Safety

CJC-1295's safety profile in the clinical trial context showed no serious adverse events. The non-DAC version's shorter half-life means any adverse effects would be transient. The DAC version's sustained action means effects — beneficial or otherwise — persist for the week.

Standard GH-related effects apply: mild water retention, occasional tingling or flushing, possible headache in the early weeks of use. These are not unique to CJC-1295 — they occur with any compound that meaningfully elevates GH.

The endocrine safety point worth emphasizing: CJC-1295 works with the GH axis rather than replacing it. The pituitary continues to function. Natural GHRH signaling continues. This is meaningfully different from exogenous growth hormone, which suppresses endogenous GH production through negative feedback.

The IGF-1 monitoring recommendation applies here as it does to all GH peptide protocols. Keeping IGF-1 within the age-appropriate reference range is the appropriate target.

The Honest Bottom Line

CJC-1295 is the missing half of the most evidence-supported GH peptide combination available. On its own, it produces a modest GH response. Combined with ipamorelin, the synergistic activation of two independent receptor systems produces a substantially amplified response that neither compound achieves alone.

The DAC vs. no DAC question is genuinely unresolved — both approaches have legitimate mechanistic rationales, and the clinical answer probably depends on individual goals and practical considerations. For protocols prioritizing physiological authenticity, no DAC. For protocols prioritizing sustained IGF-1 elevation and simplicity, DAC.

The human clinical trial data for the DAC version is a meaningful asset. The mechanistic story is well-understood. The combination with ipamorelin is the right frame for evaluating this compound — it was never designed to be used in isolation.

This article is for informational and educational purposes only. It does not constitute medical advice. CJC-1295 is not approved by the FDA for human use. Consult a licensed physician before considering any experimental compound.